<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="106042">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02112162</url>
  </required_header>
  <id_info>
    <org_study_id>201401064</org_study_id>
    <nct_id>NCT02112162</nct_id>
  </id_info>
  <brief_title>Gene Expression and FDG PET/MRI in Evaluating Treatment Response in Patients With Locally Advanced Rectal Cancer Undergoing Chemotherapy and Radiation Therapy Before Surgery</brief_title>
  <official_title>Pilot Study of Gene Expression and FDG-PET/MR Biomarkers for Evaluation of Response to Neoadjuvant Therapy for Locally Advanced Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies gene expression analysis and fludeoxyglucose F 18 (FDG)
      positron emission tomography (PET)/magnetic resonance imaging (MRI) in evaluating treatment
      response in patients with rectal cancer that has spread to nearby tissue or lymph nodes
      undergoing chemotherapy and radiation therapy before surgery. Studying samples of tissue in
      the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid
      (DNA) and may also help doctors predict a patient's response to treatment before surgery.
      PET-MRI is a procedure that combines the pictures from a PET scan and an MRI scan. The
      combined scans give more detailed pictures of areas inside the body than either scan gives
      by itself. PET-MRI may help determine how well people respond to pre-surgery chemotherapy
      and radiation therapy and help the surgeon make the best plan for removal of the tumor.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Change in FDG-PET/MR SUVmax</measure>
    <time_frame>Baseline to up to 2 weeks before surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Images will be evaluated semi-quantitatively. Changes in imaging parameters will be correlated with pathologic response.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in FDG-PET/MR SUVmean</measure>
    <time_frame>Baseline to up to 2 weeks before surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Images will be evaluated semi-quantitatively. Changes in imaging parameters will be correlated with pathologic response.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in ADCmean</measure>
    <time_frame>Baseline to up to 2 weeks before surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Images will be evaluated semi-quantitatively. Changes in imaging parameters will be correlated with pathologic response.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiosensitivity index</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Index is calculated based on tumor gene expression. Will be correlated with the descriptive changes in FDG-PET/MR SUV and ADC parameters.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Rectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Diagnostic (FDG PET/MRI, gene expression)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FDG PET/MRI at baseline and at 2-4 weeks before surgery (after neoadjuvant chemoradiation). Tissue samples for gene expression at baseline and during surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>fludeoxyglucose F 18</intervention_name>
    <description>Undergo FDG PET/MRI</description>
    <arm_group_label>Diagnostic (FDG PET/MRI, gene expression)</arm_group_label>
    <other_name>18 FDG, 18FDG, 2-F18-fluoro-2-deoxy-D-glucose, 2-F18-fluoro-2-deoxyglucose, 63503-12-8, FDG, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>positron emission tomography</intervention_name>
    <description>Undergo FDG PET/MRI</description>
    <arm_group_label>Diagnostic (FDG PET/MRI, gene expression)</arm_group_label>
    <other_name>FDG-PET, PET, PET scan, tomography, emission computed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>magnetic resonance imaging</intervention_name>
    <description>Undergo FDG PET/MRI</description>
    <arm_group_label>Diagnostic (FDG PET/MRI, gene expression)</arm_group_label>
    <other_name>MRI, NMR imaging, NMRI, nuclear magnetic resonance imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Diagnostic (FDG PET/MRI, gene expression)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy-proven adenocarcinoma of the rectum.

          -  Surgical candidate.

          -  Candidate for neoadjuvant chemotherapy.

          -  Clinical evidence of T1-3N1 or T3N0 disease. This can be either by imaging studies or
             by physical exam findings.

          -  At least 18 years of age.

          -  Zubrod performance status of 0-2.

          -  Able to understand and willing to sign a written informed consent document.

          -  Patients with distant metastatic disease will be eligible if they satisfy all other
             conditions.

        Exclusion Criteria:

          -  Pregnant.

          -  Past history of pelvic radiotherapy.

          -  Received prior chemotherapy for colorectal cancer.

          -  Uncontrolled diabetes with a fasting glucose â‰¥ 200 mg/dl at the time of PET/MRI
             imaging.

          -  Claustrophobia or any other contraindication to MRI imaging evaluated by a
             standardized safety questionnaire.

          -  Renal insufficiency (defined as glomerular filtration rate (GFR &lt; 30 mL/min/1.73 m2)
             measured no more than 60 days before the first research scan) which precludes safe
             administration of the contrast agent.

          -  Currently on dialysis.

          -  Known prior allergic reaction to gadolinium-based MR contrast agents.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Olsen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeffrey Olsen, M.D.</last_name>
    <phone>314-330-3539</phone>
    <email>jolsen@radonc.wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeffrey Olsen, M.D.</last_name>
      <phone>314-330-3539</phone>
      <email>jolsen@radonc.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Hussam Al-Kateb, M.Sc., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manik Amin, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisa Birnbaum, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Danielle Carpenter, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Farrokh Dehdashti, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Todd DeWees, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sekhar Dharmarajan, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kathryn Fowler, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yanle Hu, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Hunt, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>A. Craig Lockhart, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Mutch, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vamsi Narra, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Parag Parikh, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joel Picus, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caron Rigden, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Silviera, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Sorscher, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rama Suresh, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin Tan, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Wang-Gillam, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Wise, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 7, 2014</lastchanged_date>
  <firstreceived_date>April 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Deoxyglucose</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
